Duration of antiretroviral combinations;Duración de las combinaciones de fármacos antirretrovirales

Medicina Clinica

Volumn 122, Issue 18, 2004, Pages 696-697

  Paredes, Roger ^a,b   Clotet, Bonaventura ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; RISK FACTOR; VIRUS MUTATION; VIRUS REPLICATION;

EID: 2942625723     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13062168     Document Type: Editorial

References (20)

1. Finzi D, Blankson J, Silicano J, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999;5:512.
2. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
3. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-12.
4. Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999;13(Suppl A):137-62.
5. Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S154-7.
6. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, Van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000;160:1123-32.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
8. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003;32:522-6.
9. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently Infected with HIV. N Engl J Med 2002;347:385-94.
10. Gallego O, Ruiz L, Vallejo A, Ferrer E, Rubio A, Clotet B, et al. ERASE-3 Group. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 2001;15:1894-6.
11. Pomerantz RJ. HIV-1 reservoirs. Clin Lab Med 2002;22:651-80.
12. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925-32.
13. Piscitèlli SC, Gallicano KD. Drug therapy: interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
14. O'Brien LW. Common HIV drug-drug interactions. AIDS Read 1999;9:104-9.
15. Martínez JM, Sánchez-Rubio J, Ontañón A, Ibáñez N, Montojo C. Estudio de la durabilidad de los regímenes antirretrovirales triples. Med Clin (Barc) 2004;122:693-5.
16. Palella FJ Jr, Chmiel JS, Moorman AC, Holmberg SD; HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002;16:1617-26.
17. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37:714-22.
18. Arribas López JR, Sanz Baena S, Hernández Albujar S, Lorenzo Hernández A, Montes Ramírez ML, Palacios Muñoz R, et al: Grupo de Estudio VIHVIR+. Estudio epidemiológico retrospectivo sobre la duración del tratamiento de la infección por VIH o SIDA en España. Med Clin (Barc) 2002;119:721-4.
19. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Syder SW, Petinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 Infection. N Engl J Med 2003;349:2293-303.
20. Shafer RW, Smeaton LM, Robbins GW, De Gruttola V, Snyder SW, D'Aquila RT, et al. Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection. N Engl J Med 2003;349:2304-15.